RxDoctor Payments Data

Domingo Garcia, MD

General Practice · Miami, FLNPI 1225115397

Payments from drug & device makers

$3,480in general payments, 2019–2025

Across 173 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$635
  • Johnson & Johnson$267
  • Merck$197
  • Janssen Products, LP$165
  • Abbott$72
  • plus $213 from 6 others

What the payments were for

  • Food & beverage$3,31695%
  • Education$1655%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,480 in reported general payments places this provider in the 90th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$109
Medicare patients
18
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala53$218,521
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf39$181,768
TivicayDolutegravir Sodium14$61,570
FarxigaDapagliflozin Propanediol69$57,993
TrulicityDulaglutide50$57,611
DovatoDolutegravir Sodium/Lamivudine16$47,876
TriumeqAbacavir/Dolutegravir/Lamivudi13$44,896
OzempicSemaglutide41$39,395
JardianceEmpagliflozin21$13,950
EliquisApixaban13$7,444
Synjardy XrEmpagliflozin/Metformin Hcl12$7,386
Diclofenac Sodium68$2,881
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$2,453
Atorvastatin Calcium207$701
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$635$218,52153 claims
Janssen Products, LPSymtuza$165$181,76839 claims
Viiv Healthcare CompanyTivicay, Dovato, Triumeq$1,932$154,34343 claims
AstraZenecaFarxiga$36$57,99369 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,901 general practice providers in Florida.

Other general practice in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →